卵巢癌患者联合检测血清TK1、CA125的临床价值

目的探讨血清胸苷激酶1（TK1）、糖类抗原125（CA125）联合检测对卵巢癌患者诊断的临床价值。方法采用免疫增强化学发光法对82例卵巢癌患者（卵巢癌组）、46例良性卵巢疾病患者（良性组）及35例健康体检者（对照组）血清TKl的浓度进行检测；采用化学发光法对上述各组标本进行血清CA125的浓度进行检测，并对检测结果进行统计分析。结果卵巢癌组的血清TK1、CA125水平均显著高于良性组及对照组（P〈0．01）。两项指标联合检测，其敏感性和特异性显著高于单项检测（P〈0．05）。结论血清TK1、CA125的水平对卵巢癌的诊断具有重要价值，两种标志物联合检测效果更佳。

Clinical value of combined detection of serum TK1, CA125 in diagnosis of ovarian cancer

Objective To explore the significance of detection serum thymidine kinase 1 （ TK1 ）, carbohydrate antigen 125 （ CA125 ） in diagnosis of ovarian cancer. Methods The levels of serum TK1 were detected by enhanced chemiluminis- cence dot-blot assay in 82 patients with ovarian cancer（ ovarian cancer group） ,46 patients with benign ovarian disease （ benign disease group） and 35 health people（ control group）. The levels of serum CA125 were detected by chemilumines- cence immunoassay. Results The levels of serum TK1, CA125 in patients with ovarian cancer were significantly higher than those in patients with benign ovarian disease and control group（P 〈0.01 ）. The sensitivity, specificity and accuracy of combined detection of the two markers were significantly higher than those of single detection （ P 〈 0. 05 ）. Conclusion Serum TK1 and CA125 might have important value in diagnosis of ovarian cancer. Combined detection of the two markers could significantly improve the diagnostic value of ovarian cancer.